An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status

Lignende værker

• Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study
  af: Burmester, Gerd R, et al.
  Udgivet: (2014)
• Adalimumab alone and in combination with disease‐modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial
  af: Burmester, Gerd R, et al.
  Udgivet: (2007)
• Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis
  af: Keystone, Edward C, et al.
  Udgivet: (2018)
• Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis
  af: Rudwaleit, Martin, et al.
  Udgivet: (2010)
• Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
  af: Rudwaleit, Martin, et al.
  Udgivet: (2010)